Table 2.

Adverse events reported by untreated community members after a mass azithromycin distribution, Ethioipia^*

Adverse event	12-month survey, % (95% CI)		24-month survey, % (95% CI)
	1–9 years of age, n = 30	≥ 10 years of age, n = 150	1–9 years of age, n = 41	≥ 10 years of age, n = 161
Any	6.7 (0–14.0)	12.0 (3.1–24.2)	0 (0–8.6)	5.6 (2.4–9.8)
Abdominal pain	3.3 (0–7.0)	6.0 (0–15.0)	0 (0–8.6)	1.2 (0–4.5)
Vomiting	3.3 (0–7.0)	0.7 (0–2.6)	0 (0–8.6)	1.9 (0–5.7)
Nausea	0 (0–11.6)	2.0 (0–5.4)	0 (0–8.6)	1.2 (0–3.6)
Diarrhea	0 (0–11.6)	0 (0–2.4)	0 (0–8.6)	0.6 (0–2.5)
Dyspepsia	0 (0–11.6)	0.7 (0–2.0)	0 (0–8.6)	0 (0–2.3)
Constipation	0 (0–11.6)	0.7 (0–2.0)	0 (0–8.6)	0 (0–2.3)
Hemorrhoid	0 (0–11.6)	2.0 (0.5–3.9)	0 (0–8.6)	0 (0–2.3)
Rash	0 (0–11.6)	0 (0–2.4)	0 (0–8.6)	0 (0–2.3)
Other	0 (0–11.6)	1.3 (0–3.6)	0 (0–8.6)	1.9 (0–3.7)

^*CI = confidence interval. Because persons may have more than one adverse event, the sum of individual adverse events does not equal the percentage with any adverse event.